Vaxcyte, Inc. (PCVX)
$
31.73
-0.81 (-2.55%)
Key metrics
Financial statements
Free cash flow per share
-4.4219
Market cap
4.2 Billion
Price to sales ratio
0
Debt to equity
0.0273
Current ratio
17.6973
Income quality
0.9022
Average inventory
0
ROE
-0.1712
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops innovative protein vaccines aimed at preventing or treating bacterial infectious diseases. Its lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials targeting invasive pneumococcal disease and pneumonia. The company's stock is identified with the symbol 'PCVX' in the market, highlighting its presence within the investment community. Vaxcyte achieved a revenue of $0.00 indicating its niche market focus and commitment to advancing its vaccine candidates. The diluted EPS is -$3.80 accounting for potential share dilution, while the gross profit stands at $0.00 showcasing the company's profitability from core operations. Additionally, the earnings per share (EPS) is reported at -$3.80 reflecting the company's financial performance on a per-share basis. Alongside its lead candidate, Vaxcyte is actively developing VAX-XP to address emerging bacterial strains and combat antibiotic resistance, VAX-A1, a conjugate vaccine targeting Group A Streptococcus, and VAX-PG, a novel protein vaccine aimed at the keystone pathogen responsible for periodontitis. The company, previously known as SutroVax, Inc. until its name change in May 2020, was incorporated in 2013 and operates from its headquarters in San Carlos, California. The stock is reasonably priced at $31.73 appealing to a broad range of investors seeking opportunities in the biotechnology landscape. With a high average trading volume of 2,511,266.00 the stock indicates strong liquidity, which is beneficial for investors looking for flexibility in their transactions. Vaxcyte boasts a mid-range market capitalization of $4,093,296,888.00 positioning the company as a steady performer in the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, which drives innovation and growth. These attributes collectively enhance Vaxcyte's profile as a promising investment opportunity while highlighting its role in advancing health solutions through its vaccine development efforts.
Is Vaxcyte, Inc. (PCVX) a good investment?
Investing in Vaxcyte, Inc. (PCVX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Vaxcyte, Inc. (PCVX)'s stock forecast?
Analysts predict Vaxcyte, Inc. stock to fluctuate between $27.66 (low) and $121.06 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Vaxcyte, Inc.'s market capitalization?
As of 2025-05-27, Vaxcyte, Inc.'s market cap is $4,093,296,888, based on 129,003,999 outstanding shares.
How does Vaxcyte, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Vaxcyte, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Vaxcyte, Inc. (PCVX) stock?
To buy Vaxcyte, Inc. (PCVX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PCVX. Place an order (Market, Limit, etc.).
What is the best time to invest in Vaxcyte, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Vaxcyte, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.80 | Growth: -8.21%.
Where can I find Vaxcyte, Inc.'s investor relations reports?
Visit https://vaxcyte.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Vaxcyte, Inc.?
You can explore historical data from here
What is the all-time high and low for Vaxcyte, Inc. stock?
All-time high: $121.06 (2024-09-19) | All-time low: $15.51 (2021-05-11).
What are the key trends affecting Vaxcyte, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
21 days ago
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later --
globenewswire.com
a month ago
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
zacks.com
2 months ago
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
zacks.com
2 months ago
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
seekingalpha.com
2 months ago
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
benzinga.com
2 months ago
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants.
globenewswire.com
2 months ago
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formulation for Advancement to Potential Infant Phase 3 Program, Pending Topline VAX-31 Infant Phase 2 Study Readout -- -- Company Announces VAX-XL, Third-Generation PCV Candidate Designed to Further Expand Spectrum of Coverage -- -- Company to Host Webcast/Conference Call Today at 8:00 a.m. ET / 5:00 a.m.
globenewswire.com
2 months ago
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.
seekingalpha.com
3 months ago
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call.
globenewswire.com
3 months ago
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 --
See all news
